Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?


OBJECTIVES:Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS:A retrospective study was performed at two academic cancer centers. Patients with Stage II-IV LGSC underwent either primary or interval CRS followed by adjuvant HT between 2004 and 2016. Gynecologic pathologists reviewed all cases. Two-year progression-free (PFS) and overall survival (OS) were calculated. RESULTS:Twenty-seven patients were studied; primary CRS followed by HT were administered in 26, while 1 patient had neoadjuvant chemotherapy followed by CRS and HT. The median patient age was 47.5, and patients had Stage II (n=2), Stage IIIA (n=6), Stage IIIC (n=18), and Stage IV (n=1) disease. Optimal cytoreduction to no gross residual was achieved in 85.2%. Ninety six percent of tumors expressed estrogen receptors, while only 32% expressed progesterone receptors. Letrozole was administered post operatively in 55.5% cases, anastrozole in 37.1% and tamoxifen in 7.4%. After a median follow up of 41months, only 6 patients (22.2%) have developed a tumor recurrence and two patients have died of disease. Median PFS and OS have not yet been reached, but 2-year PFS and OS were 82.8% and 96.3%, respectively, and 3-year PFS and OS were 79.0% and 92.6%, respectively. CONCLUSIONS:Our series describes the initial experience with cytoreductive surgery and hormonal monotherapy for women with Stage II-IV primary ovarian LGSC. While surgery remains the mainstay of treatment, chemotherapy may not be necessary in patients with advanced-stage disease who receive adjuvant hormonal therapy. A cooperative group, Phase III trial is planned to define the optimal therapy for women with this ovarian carcinoma subtype.


Gynecol Oncol


Gynecologic oncology


Fader AN,Bergstrom J,Jernigan A,Tanner EJ 3rd,Roche KL,Stone RL,Levinson KL,Ricci S,Wethingon S,Wang TL,Shih IM,Yang B,Zhang G,Armstrong DK,Gaillard S,Michener C,DeBernardo R,Rose PG




Has Abstract


2017-10-01 00:00:00














  • Carcinoma of the cervix with extensive endometrial and myometrial involvement.

    abstract::Verrucous carcinoma is a rare variant of epidermoid carcinoma with distinct clinical and histopathologic features. To date, 31 cases have been reported in the cervix. They are typically slow-growing, locally invasive tumors with low potential for lymphatic metastasis and appear to be radioresistant. We report a case w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审


    authors: de Jesus M,Tang W,Sadjadi M,Belmonte AH,Poon TP

    更新日期:1990-02-01 00:00:00

  • Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.

    abstract:OBJECTIVE:In Denmark, the proportion of women with ovarian cancer treated with neoadjuvant chemotherapy (NACT) has increased, and the use of NACT varies among center hospitals. We aimed to evaluate the impact of first-line treatment on surgical outcome and median overall survival (MOS). METHODS:All patients treated in...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Fagö-Olsen CL,Ottesen B,Kehlet H,Antonsen SL,Christensen IJ,Markauskas A,Mosgaard BJ,Ottosen C,Soegaard CH,Soegaard-Andersen E,Hoegdall C

    更新日期:2014-02-01 00:00:00

  • Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance.

    abstract:OBJECTIVE:The placental site trophoblastic tumor is a rare form of gestational trophoblastic disease. Fifteen percent of reported cases have been fatal, but predicting behavior in individual patients has been challenging. METHODS:The clinical, gross and histopathological features of 55 cases and 180 cases in the liter...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Baergen RN,Rutgers JL,Young RH,Osann K,Scully RE

    更新日期:2006-03-01 00:00:00

  • POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

    abstract:OBJECTIVE:To identify molecular prognosticators and therapeutic targets for high-grade serous epithelial ovarian cancers (EOCs) using genetic analyses driven by biologic features of EOC pathogenesis. METHODS:Ovarian tissue samples (n = 172; 122 serous EOCs, 30 other EOCs, 20 normal/benign) collected prospectively from...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Karlan BY,Dering J,Walsh C,Orsulic S,Lester J,Anderson LA,Ginther CL,Fejzo M,Slamon D

    更新日期:2014-02-01 00:00:00

  • The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas.

    abstract::From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7% of cases, mucinous tumors 20.4%, endometrioid tumors 16%, and other epithelial tumors 19.4...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Altaras MM,Goldberg GL,Levin W,Bloch B,Darge L,Smith JA

    更新日期:1988-05-01 00:00:00

  • Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach.

    abstract:OBJECTIVE:The natural history of the development of ovarian carcinoma is not known. It also remains undetermined whether ovarian carcinomas develop from benign and/or borderline malignant tumors or arise de novo from the ovarian surface epithelium. METHODS:To address these issues clinicopathologically, we reviewed the...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究


    authors: Horiuchi A,Itoh K,Shimizu M,Nakai I,Yamazaki T,Kimura K,Suzuki A,Shiozawa I,Ueda N,Konishi I

    更新日期:2003-03-01 00:00:00

  • A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

    abstract:OBJECTIVE:To assess the safety and efficacy of pegylated liposomal doxorubicin (PLD), carboplatin, plus bevacizumab in patients with ovarian, fallopian tube, or primary peritoneal cancer. METHODS:Patients with platinum-sensitive, recurrent disease received PLD 30 mg/m(2) and carboplatin area under the curve (AUC) 5 on...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究


    authors: del Carmen MG,Micha J,Small L,Street DG,Londhe A,McGowan T

    更新日期:2012-09-01 00:00:00

  • Psychological adjustment to familial-genetic risk assessment for ovarian cancer: predictors of nonadherence to surveillance recommendations.

    abstract:OBJECTIVE:To evaluate whether self-report measures of psychological distress and perceived risk were associated with nonadherence to recommended ovarian cancer surveillance. METHODS:Eighty-three patients attending the Familial Ovarian Cancer Clinic (FOCC) at Princess Margaret Hospital were assessed psychosocially prio...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Ritvo P,Irvine J,Robinson G,Brown L,Murphy KJ,Matthew A,Rosen B

    更新日期:2002-01-01 00:00:00

  • The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data.

    abstract:OBJECTIVE:This article critically reviews the literature on the association between endometriosis and gynecological cancers and breast cancer, based on epidemiologic data. METHODS:Literature review of the English language literature based on searching in the MEDLINE (PubMed) database and additional collection of repor...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审


    authors: Munksgaard PS,Blaakaer J

    更新日期:2011-10-01 00:00:00

  • Establishment and characterization of ovarian endometrioid carcinoma cell line.

    abstract::Ascitic fluid was obtained from a patient with ovarian endometrioid carcinoma. The cells obtained from the fluid were cultured in Eagle's minimum essential medium containing 15% fetal calf serum at 37 degrees C under humidified 5% CO2 and 95% air. Epithelial colonies grew rapidly in the primary culture and we were abl...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Uehara S,Abe H,Hoshiai H,Yajima A,Suzuki M

    更新日期:1984-03-01 00:00:00

  • Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.

    abstract:OBJECTIVE:The aberrant expression of hepatocyte growth factor and its receptor c-Met are associated with aggressive disease and poor prognosis in a variety of human malignancies including ovarian cancer (OC). Specificity protein (Sp) transcription factors have high relevance in the signaling cascade associated with c-M...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Basha R,Ingersoll SB,Sankpal UT,Ahmad S,Baker CH,Edwards JR,Holloway RW,Kaja S,Abdelrahim M

    更新日期:2011-07-01 00:00:00

  • Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy.

    abstract:PURPOSE:To evaluate the long-term disease control, survival and complication rates using high-dose-rate intracavitary brachytherapy (HDRB) and external beam radiotherapy (EBRT) for patients found to have isolated vaginal recurrences from early-stage endometrial adenocarcinoma following total abdominal hysterectomy and ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审


    authors: Pai HH,Souhami L,Clark BG,Roman T

    更新日期:1997-08-01 00:00:00

  • Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.

    abstract:OBJECTIVES:To determine if SAHA, a histone deacetylase inhibitor, decreases ovarian cancer cell viability when combined with paclitaxel in vitro, and to explore molecular alterations of combined paclitaxel+SAHA treatment. METHODS:SKOV3 and Hey ovarian cancer cell lines were treated for 24 h with paclitaxel, then re-tr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Dietrich CS 3rd,Greenberg VL,DeSimone CP,Modesitt SC,van Nagell JR,Craven R,Zimmer SG

    更新日期:2010-01-01 00:00:00

  • Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.

    abstract:OBJECTIVE:The study aims at identifying novel markers for circulating tumor cells (CTCs) in patients with epithelial ovarian cancer (EOC), and at evaluating their impact on outcome. METHODS:Microarray analysis comparing matched EOC tissues and peripheral blood leucocytes (N=35) was performed to identify novel CTC mark...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Obermayr E,Castillo-Tong DC,Pils D,Speiser P,Braicu I,Van Gorp T,Mahner S,Sehouli J,Vergote I,Zeillinger R

    更新日期:2013-01-01 00:00:00

  • Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer.

    abstract:OBJECTIVE:The purpose of the present study is to prospectively evaluate the effects of tamoxifen on the pathological behavior of endometrial hyperplasias without atypia, diagnosed before the start of adjuvant endocrine therapy, in menopausal patients suffering from breast cancer. METHODS:Twenty-six patients suffering ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Garuti G,Cellani F,Centinaio G,Sita G,Nalli G,Luerti M

    更新日期:2006-05-01 00:00:00

  • Immunohistochemical detection of somatostatin receptors in human ovarian tumors.

    abstract:OBJECTIVE:It is well established that many human tumors can express somatostatin receptors. This is the molecular basis for the application of long-acting somatostatin analogues for therapeutic and diagnostic purposes. However, there are discrepancies in earlier studies regarding the prevalence of somatostatin receptor...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Schulz S,Schmitt J,Quednow C,Roessner A,Weise W

    更新日期:2002-02-01 00:00:00

  • Treatment for fertility and risk of ovarian tumors of borderline malignancy.

    abstract::The relationship between fertility drug use and risk of borderline ovarian cancer has been analyzed using data from a case-control study. Cases were 93 women aged 23 to 64 years with histologically confirmed diagnosis of borderline ovarian tumor (according to the World Health Organization criteria) who were admitted t...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Parazzini F,Negri E,La Vecchia C,Moroni S,Polatti A,Chiaffarino F,Surace M,Ricci E

    更新日期:1998-03-01 00:00:00

  • Current techniques in screening for cervical cancer in Spain: updated recommendations.

    abstract::A population-based survey (AFRODITA Study) was conducted in Spain in order to estimate the coverage and factors associated with cervical cancer cytological screening. The results of this survey indicate that the rate of screening for cervical cancer in Spain is 75.6% in women between 18 and 65 years. This high rate of...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Puig-Tintoré LM,Torné A,Alonso I

    更新日期:2008-09-01 00:00:00

  • The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome.

    abstract:OBJECTIVE:Based on previous studies, standard gynecological screening consisting of annual transvaginal ultrasonography (TVU) was added with endometrial sampling in women with Lynch syndrome (LS). The aim of this study was to evaluate the additional value of endometrial sampling in detecting (pre)malignancies of the en...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Helder-Woolderink JM,De Bock GH,Sijmons RH,Hollema H,Mourits MJ

    更新日期:2013-11-01 00:00:00

  • Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.

    abstract:OBJECTIVE:The aim of this study was to establish a reference 24-hour urine human chorionic gonadotropin (hCG) regression curve in patients with complete hydatidiform mole (CHM) as diagnostic tool in the prediction of persistent trophoblastic disease (PTD). METHODS:From 2004 to 2011, 312 cases suitable for this study w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: van Cromvoirt SM,Thomas CM,Quinn MA,McNally OM,Bekkers RL

    更新日期:2014-06-01 00:00:00

  • Synovial cell sarcoma of the vulva: multimodality treatment incorporating preoperative external-beam radiation, hemivulvectomy, flap reconstruction, interstitial brachytherapy, and chemotherapy.

    abstract:BACKGROUND:Vulvar synovial cell sarcomas are rare, with only four previously published cases in the literature. Traditionally, the primary management for these tumors has been surgery alone. CASE:We report a case of a large vulvar synovial cell sarcoma in a 50-year-old woman treated with comprehensive combined multimo...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Holloway CL,Russell AH,Muto M,Albert M,Viswanathan AN

    更新日期:2007-01-01 00:00:00

  • K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.

    abstract:OBJECTIVE:Müllerian inclusion cysts (MIC) are small benign appearing glands that are occasionally noted in lymph nodes and peritoneal biopsies. They occur most frequently in women with serous ovarian tumors, with borderline tumors (SBOT) having a higher incidence than invasive cancers. The aim of this study was to exam...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Alvarez AA,Moore WF,Robboy SJ,Bentley RC,Gumbs C,Futreal PA,Berchuck A

    更新日期:2001-02-01 00:00:00

  • Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms.

    abstract:OBJECTIVE:The goals of this study were to evaluate the feasibility of pelvic intensity-modulated radiotherapy (IMRT) in the adjuvant treatment of gynecologic malignancies and to compare the dose-volume histograms (DVHs) and determine the potential impact on acute and long-term toxicity based on the dose to target and n...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章


    authors: Heron DE,Gerszten K,Selvaraj RN,King GC,Sonnik D,Gallion H,Comerci J,Edwards RP,Wu A,Andrade RS,Kalnicki S

    更新日期:2003-10-01 00:00:00

  • Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study.

    abstract:OBJECTIVE:To evaluate the feasibility of an electronic symptom-tracking platform for patients recovering from ambulatory surgery. METHOD:We assessed user response to an electronic system designed to self-report symptoms. Endpoints included compliance, postoperative symptoms, patient satisfaction. An 8-item symptom inv...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Zivanovic O,Chen LY,Vickers A,Straubhar A,Baser R,Veith M,Aiken N,Carter J,Curran K,Simon B,Mueller J,Jewell E,Chi DS,Sonoda Y,Abu-Rustum NR,Leitao MM Jr

    更新日期:2020-10-01 00:00:00

  • Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.

    abstract:OBJECTIVE:Members of the glutathione S-transferase (GST) family have been shown to have functional polymorphisms that may affect drug metabolism and influence the effects of chemotherapy and survival from cancer. GSTM1, GSTT1, and GSTP1 genotypes were evaluated for their role in ovarian cancer treatment and survival. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Beeghly A,Katsaros D,Chen H,Fracchioli S,Zhang Y,Massobrio M,Risch H,Jones B,Yu H

    更新日期:2006-02-01 00:00:00

  • Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.

    abstract:OBJECTIVE:Mucinous borderline ovarian tumor (mucinous-BOT) and invasive well-differentiated mucinous ovarian cancer (mucinous-OC) are often histopathologically misclassified. The objective of this study was to examine differences in clinico-pathological characteristics and outcomes of these two entities. METHODS:This ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Matsuo K,Machida H,Mandelbaum RS,Grubbs BH,Roman LD,Sood AK,Gershenson DM

    更新日期:2019-05-01 00:00:00

  • Malignant struma ovarii: recurrence and response to treatment monitored by thyroglobulin levels.

    abstract::A patient with malignant struma ovarii who had elevated thyroglobulin levels at the time of her original surgery was diagnosed with recurrence on the basis of progressive thyroglobulin level elevation while on thyroid suppressive therapy. Subsequent treatment with therapeutic doses of iodine-137 resulted in normalizat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Rose PG,Arafah B,Abdul-Karim FW

    更新日期:1998-09-01 00:00:00

  • Clinical audit in gynecological cancer surgery: development of a risk scoring system to predict adverse events.

    abstract:BACKGROUND:Advanced gynecological surgery undertaken in a specialized gynecologic oncology unit may be associated with significant perioperative morbidity. Validated risk prediction models are available for general surgical specialties but currently not for gynecological cancer surgery. OBJECTIVE:The objective of this...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Kondalsamy-Chennakesavan S,Bouman C,De Jong S,Sanday K,Nicklin J,Land R,Obermair A

    更新日期:2009-12-01 00:00:00

  • A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.

    abstract::Fourteen patients with malignant nondysgerminomatous germ-cell tumors of the ovary were treated with a combination of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen). Nine patients received PVeBV as primary postoperative therapy, of whom four had no residual disease. Four patients received P...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章


    authors: Culine S,Kattan J,Lhomme C,Duvillard P,Michel G,Castaigne D,Leclere J,Pico J,Droz JP

    更新日期:1994-07-01 00:00:00

  • Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.

    abstract:OBJECTIVE:The objective of this study is to examine the outcomes of combined chemotherapy using methotrexate and dactinomycin in the management of women with low-risk gestational trophoblastic neoplasia (GTN). The primary outcome is the total number of cycles of chemotherapy required to achieve a normal level of human ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章


    authors: Eiriksson L,Wells T,Steed H,Schepansky A,Capstick V,Hoskins P,Pike J,Swenerton K

    更新日期:2012-03-01 00:00:00